Covid-19
-
China sees another inactivated novel coronavirus vaccine that has big potential
An inactivated novel coronavirus vaccine called BBIBP-CorV from a Chinese team has shown great potential in animal studies.
-
BYD N95 masks finally certified, will supply 150 million to California
California Governor Gavin Newsom announced on June 8 that the BYD N95 masks have obtained the National Institute for Occupational Safety and Health (NIOSH) certification, BYD will continue to supply N95 masks to California.
-
Another China-made nucleic acid test kit authorized for emergency use in U.S.
Beijing-based Genetron Health's novel coronavirus kit receives U.S. EUA approval after receiving CE mark in the European Union
-
World's first coronavirus-neutralizing antibody from Chinese team enters clinical trial
The recombinant human anti-new coronavirus monoclonal antibody injection (JS016) developed by a Chinese team has been approved by the State Drug Administration (SFDA) to enter Phase I clinical trials.
-
China's first Covid-19 therapeutic antibody drug approved for clinical trial
Recently, Yan Jinghua's team at the Institute of Microbiology, Chinese Academy of Sciences, developed a new fully humanized monoclonal antibody against coronavirus, which was approved for clinical trials, according to the Beijing Daily.
-
First coronavirus neutralizing antibody kit can detect whether the body is immune in 1 hour
Whether the body has developed immunity to the new coronavirus, the results can be obtained within an hour after testing with this kit.
-
Samsung launches smartwatch app to help users develop hand-washing habits
Washing your hands has always been an important way to prevent the spread of viruses, but with the COVID-19 pandemic, it's more important than ever to get into the habit.
-
World's first human clinical trial of antibody drug against Covid-19 begins
Eli Lilly announced today that its Phase 1 study of the primary antibody LY-CoV555, developed in collaboration with AbCellera, has been administered to the first patients.
-
Gilead says treatment with remdesivir 65% more likely to have improvement
Patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group, according to Gilead Sciences's phase 3 trial of Remdesivir in patients with moderate Covid-19.
-
Five coronavirus vaccines have entered Phase II trials in China
China is among the first in the world in terms of vaccine development, with five vaccines currently in Phase II clinical trials.